Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
CRWD 38.08CRM 46.33NVDA 17.44KEL.TO 0.22WPM.TO 2.65X.TO -0.14ODD 0.08CDI.PA-O 0
AbbVie Inc. (ABBV)

NYSE:ABBV

AbbVie Inc. (ABBV)

257.66
-5.24 (1.99%)
as of Aug 27, 2026, 5:02:07 pm Market Open.
336 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 27, 2026, 12:00 am

This summary was created by AI, based on 7 opinions in the last 12 months.

AbbVie Inc. is receiving positive reviews from experts, highlighting the company's robust performance despite the patent expiration of its blockbuster drug, Humira. The recent Q2 earnings report showcased an impressive total net revenue increase of 10.2%, driven by significant sales growth from new drugs like Skyrizi and Rinvoq. Experts note that AbbVie has successfully managed the transition by replacing lost revenues with innovative products, projecting strong revenue growth of 24% going forward. The stock has seen fluctuations, appreciating 6% in the past month and 15% over the past year, establishing itself as a solid holding in the healthcare sector with less execution risk. Overall, the sentiment is optimistic about AbbVie's future prospects, fueled by a promising pipeline and effective management strategies addressing current challenges.

consensus icon
Consensus
Positive
valuation icon
Valuation
Fair Value
review icon
Similar
PFE
BUY

AbbVie Inc.(ABBV)

Mar 23, 2022
She just trimmed her holding last week, because it's done very well. Their drug pipeline looks positive. Healthcare is her second-favourite sector and this is a great way to play it.
Photo of Shannon Saccocia, CIO, Boston PrivateShannon Saccocia, CIO, Boston Private
Owned
Unlock Rating
$158.93

Stock price when the opinion was issued

$257.94

As of Aug 27, 2026. Market Open.

0
COMMENT

AbbVie Inc.(ABBV)

Mar 14, 2022
They have done well recently but he is looking for companies with longer term potential and expiry dates for drug patents. Should have good pipelines. Prefers diabetic care companies since this disease is on the rise. eg. Eli Lilly or Novo Nordisk. Astra Zeneca has a good pipeline in oncology drugs.
Photo of David FingoldDavid FingoldUnlock Rating
$152.10

Stock price when the opinion was issued

$257.94

As of Aug 27, 2026. Market Open.

0
SELL

AbbVie Inc.(ABBV)

Mar 10, 2022
Great dividend, low valuation at 10x, and growing well, but he grabbed an exit point, as 43% of revenue comes from a drug going off patent next year. Pricing pressures mean that ABBV will see a decline in revenues and cashflows. Did well, but time to leave in favour of companies well off their highs.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$149.01

Stock price when the opinion was issued

$257.94

As of Aug 27, 2026. Market Open.

0
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

AbbVie Inc.(ABBV)

Mar 08, 2022
(A Top Pick Apr 22/21, Up 32.6%)Stockchase Research Editor: Michael O’Reilly Our PAST TOP PICK with ABBV is progressing well. To remain disciplined, we now recommend trailing up the stop (from $130) to $140.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$147.15

Stock price when the opinion was issued

$257.94

As of Aug 27, 2026. Market Open.

0
BUY

AbbVie Inc.(ABBV)

Feb 18, 2022
Another strong report earlier this month with 13% EPS growth and pays a nice dividend above 4%. Good for this market.
Photo of Jason Snipe, CIO, Odyssey Capital AdvisorsJason Snipe, CIO, Odyssey Capital AdvisorsUnlock Rating
$144.03

Stock price when the opinion was issued

$257.94

As of Aug 27, 2026. Market Open.

0
BUY

AbbVie Inc.(ABBV)

Feb 14, 2022
It pays a dividend under 4%, and dividend growth has been 10% in the last three years. Also, it boasts a very low beta of 0.82.
Photo of Joe TerranovaJoe TerranovaUnlock Rating
$141.86

Stock price when the opinion was issued

$257.94

As of Aug 27, 2026. Market Open.

0
BUY

AbbVie Inc.(ABBV)

Feb 08, 2022
It's done extremely well for him, but he's watching this carefully. Trades under 10x earnings and pays a 4% dividend. It's been growing well on their very successful Humera drug, but that goes off-patent in 2023. So, ABBV is working hard to fill that gap. They have a few promising drugs ramping up, but they will need to ramp up to the $10 billion range to fill Humera's shoes. A few years ago, they bought Botox which long-term will be good for ABBV, despite a slowdown during Covid. He still likes ABBV, but is keeping an eye on it in case earnings stall.
Photo of Gordon ReidGordon Reid
Owned
Unlock Rating
$142.80

Stock price when the opinion was issued

$257.94

As of Aug 27, 2026. Market Open.

0
PAST TOP PICK

AbbVie Inc.(ABBV)

Feb 03, 2022
(A Top Pick Feb 11/21, Up 40%) Still likes it. Clever acquisitions, which have started to backfill their R&D pipeline. Two of their next generation drugs are really taking the place of those coming off patent, and market is rewarding them for that. Technical breakout this morning, perhaps due to momentum trading. Great dividend. Hold, but probably not a Top Pick today.
Photo of Paul MacDonaldPaul MacDonald
Owned
Unlock Rating
$141.21

Stock price when the opinion was issued

$257.94

As of Aug 27, 2026. Market Open.

0
Track your Stocks in your Watch List
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

AbbVie Inc.(ABBV)

Feb 03, 2022
(A Top Pick Apr 22/21, Up 26.3%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with ABBV is progressing well. We now recommend trailing up the stop (from $112) to $130.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$141.21

Stock price when the opinion was issued

$257.94

As of Aug 27, 2026. Market Open.

0
BUY ON WEAKNESS

AbbVie Inc.(ABBV)

Jan 28, 2022
They report Wednesday. It has a lot of new drugs. It yields 4.1%. He expects a good year from them. But wait because it's had such as a good run.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad Money
Owned
Unlock Rating
$137.92

Stock price when the opinion was issued

$257.94

As of Aug 27, 2026. Market Open.

0
COMMENT

AbbVie Inc.(ABBV)

Jan 17, 2022
An advisor could help the caller decide whether to hold or sell some. He doesn't own either The devices made by Abbott show promise for the stock so there is upside. The pharmaceutical side is not of particular interest. These are relatively defensive stocks but market could gravitate to cyclicals.
Photo of David FingoldDavid FingoldUnlock Rating
$135.87

Stock price when the opinion was issued

$257.94

As of Aug 27, 2026. Market Open.

0
BUY ON WEAKNESS

AbbVie Inc.(ABBV)

Jan 12, 2022
He recently took some profits after a huge gain. If this falls back to $100, he'll buy again.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad Money
Owned
Unlock Rating
$137.29

Stock price when the opinion was issued

$257.94

As of Aug 27, 2026. Market Open.

0
BUY

AbbVie Inc.(ABBV)

Jan 05, 2022
Loves it. Looks fantastic, should be in your portfolio. Model price of $216.72, 60% upside. Yield is 3.85%.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$137.42

Stock price when the opinion was issued

$257.94

As of Aug 27, 2026. Market Open.

0
COMMENT

AbbVie Inc.(ABBV)

Dec 29, 2021
Hitting a 52-week high today. If your shares have run like Jim Cramer's have since 2019, then sure take some profits. That's fine, but his own position is smaller and he's hanging on.
Photo of Joe TerranovaJoe Terranova
Owned
Unlock Rating
$135.44

Stock price when the opinion was issued

$257.94

As of Aug 27, 2026. Market Open.

0
Showing 76 to 90 of 178 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

PFE -0.295$28.005
NOW 12.58$138.38
BRK.B -1.9$503.01
FTS.TO -0.74$76.05
ATH.TO 0.26$10.94

Today's Top Picks

CRWD 38.08$227.26
CRM 46.33$251.95
NVDA 17.44$227.1
KEL.TO 0.22$10.87
WPM.TO 2.65$218.99

Popular Articles

Latest Sell Signals

CLS.TO 13.49$439.65
TJX -1.95$134.88
ORCL 1.91$150.78
GAW-LSE 0$
BB.TO 1.05$11.85

Most Recent Experts

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Javed Mirza

Javed Mirza

Raymond James

Bill Baruch, Founder, Blue Line Capital

Bill Baruch, Founder, Blue Line Capital

Blue Line Capital

Karen Firestone, CEO, Aureus Asset Management

Karen Firestone, CEO, Aureus Asset Management

Aureus Asset Management

Joe Terranova

Joe Terranova

Virtus Investment Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like